MUC1 and pancreatic neoplasm: As both WT1 and MUC1 are one of the excellent TAAs for the target of immunotherapy and are frequently expressed in pancreatic cancer cells [36, 37, 123, 130], 38 out of 49 patients had received vaccination with WT1 peptide-pulsed DCs with or without combination of other peptides such as MUC1, CEA, and CA125 in this report.